Intravenous immunoglobulin (IVIg) provides protection against endothelial cell dysfunction and death in ischemic stroke

Experimental and Translational Stroke Medicine

Volumn 6, Issue 1, 2014, Pages

  Widiapradja, Alexander ^a,b   Santro, Tomislav ^b   Basta, Milan ^c   Sobey, Christopher G ^d   Manzanero, Silvia ^b   Arumugam, Thiruma V ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c BioVisions Inc   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Blood brain barrier; Endothelium; Intravenous immunoglobulin; Ischemic stroke; Permeability

Indexed keywords

APOPTOSIS INDUCING FACTOR; CLAUDIN 5; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; JUNCTIONAL ADHESION MOLECULE A; NEUROPROTECTIVE AGENT; OCCLUDIN; PROTEIN BCL 2; PROTEIN BCL XL; TIGHT JUNCTION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPE; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXYGEN AND GLUCOSE DEPRIVATION; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION;

EID: 84902734085     PISSN: None     EISSN: 20407378     Source Type: Journal    
DOI: 10.1186/2040-7378-6-7     Document Type: Article

References (16)

1. McCormack PL. Immune globulin (human) 10% liquid: a review of its use in primary immunodeficiency disorders. BioDrugs 2013, 27:393-400. 10.1007/s40259-013-0044-3, 23703447.
2. Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S, Magnus T, Chan SL, Jo DG, Ouyang X, Fairlie DP, Granger DN, Vortmeyer A, Basta M, Mattson MP. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 2007, 104:14104-14109. 10.1073/pnas.0700506104, 1955802, 17715065.
3. Widiapradja A, Vegh V, Lok KZ, Manzanero S, Thundyil J, Gelderblom M, Cheng YL, Pavlovski D, Tang SC, Jo DG, Magnus T, Chan SL, Sobey CG, Reutens D, Basta M, Mattson MP, Arumugam TV. Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. J Neurochem 2012, 122:321-332. 10.1111/j.1471-4159.2012.07754.x, 22494053.
4. Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, Bernreuther C, Glatzel M, Cheng YL, Thundyil J, Widiapradja A, Lok KZ, Foo SL, Wang YC, Li YI, Drummond GR, Basta M, Magnus T, Jo DG, Mattson MP, Sobey CG, Arumugam TV. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 2013, 4:e790. 10.1038/cddis.2013.326, 3789184, 24008734.
5. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40:1849-1857. 10.1161/STROKEAHA.108.534503, 19265055.
6. Issekutz AC, Rowter D, Macmillan HF. Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-α-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration. Clin Immunol 2011, 141:187-196. 10.1016/j.clim.2011.08.003, 21917526.
7. Jang JE, Hidalgo A, Frenette PS. Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1. Circ Res 2012, 110:1057-1066. 10.1161/CIRCRESAHA.112.266411, 3351009, 22415018.
8. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol 2008, 45:4073-4079. 10.1016/j.molimm.2008.07.012, 18706699.
9. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008, 32:200-219. 10.1016/j.nbd.2008.08.005, 18790057.
10. Tunik S, Aluclu MU, Acar A, Akkoc H, Guzel A, Alabalik U, Akkus M. The effects of intravenous immunoglobulin on cerebral ischemia in rats: an experimental study. Toxicol Ind Health 2013, [Epub ahead of print].
11. Walberer M, Nedelmann M, Ritschel N, Mueller C, Tschernatsch M, Stolz E, Bachmann G, Blaes F, Gerriets T. Intravenous immunoglobulin reduces infarct volume but not edema formation in acute stroke. Neuroimmunomodulation 2010, 17:97-102. 10.1159/000258692, 19923854.
12. Rodrigues SF, Granger DN. Leukocyte-mediated tissue injury in ischemic stroke. Curr Med Chem 2014, 21:2130-2137. 10.2174/0929867321666131228192119, 24372215.
13. Fernández-López D, Faustino J, Daneman R, Zhou L, Lee SY, Derugin N, Wendland MF, Vexler ZS. Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. J Neurosci 2012, 32:9588-9600. 10.1523/JNEUROSCI.5977-11.2012, 3539825, 22787045.
14. Esen F, Senturk E, Ozcan PE, Ahishali B, Arican N, Orhan N, Ekizoglu O, Kucuk M, Kaya M. Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis. Crit Care Med 2012, 40:1214-1220. 10.1097/CCM.0b013e31823779ca, 22202704.
15. St-Amour I, Paré I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J, Vandal M, Soulet D, Bazin R, Calon F. Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab 2013, 33:1983-1992. 10.1038/jcbfm.2013.160, 24045402.
16. Sawant DA, Tharakan B, Wilson RL, Stagg HW, Hunter FA, Childs EW. Regulation of tumor necrosis factor-α-induced microvascular endothelial cell hyperpermeability by recombinant B-cell lymphoma-extra large. J Surg Res 2013, 184:628-637. 10.1016/j.jss.2013.04.079, 23731686.